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Background - Anthracycline cardiomyopathy contributes to the morbidity and mortality of 
cancer survivors, but long-term data are lacking. This study sought to describe the phenotype of 
anthracycline cardiomyopathy, the prevalence of myocardial fibrosis and its association with 
cardiac remodelling, systolic function and clinical outcomes in the long-term. 
 
Methods and Results We undertook contrast-enhanced CMR in 81 cancer survivors at median 5 
years after anthracycline (mean dose 279 SD 89mg/m2). Participants were aged 55 SD 14 years; 
68% were female. Mean LVEF was impaired (49 SD 12%), driven by a pathological increase in 
iLVESV (47 SD 23ml/m2). 19% of participants exhibited LGE, which was associated with 
significant adverse left ventricular remodelling and reduced systolic function (iLVEDV: 102  SD 
34vs83 SD 21ml/m2, p=0.03; iLVESV 61 SD 32vs43 SD 20ml/m2, p=0.03; LVEF: 43 SD 
11vs50 SD 12%, p=0.03). In subgroup analysis of 36 patients, 36% had elevated native T1 
measurements, which was associated with significant adverse left ventricular remodelling 
(iLVEDV: 97 SD 22vs74 SD 19ml/m2, p=0.002; iLVESV: 56 SD 22vs35 SD15ml/m2, p=0.005), 
reduced systolic function (LVEF 44 SD 13 vs 55 SD 9%, p=0.01), and hospitalizations for heart 
failure (38%vs9%, p=0.03). Absolute native T1 measurements correlated significantly with 
iLVEDV (p =<0.001, R20.33), iLVESV (p<0.001, R20.36), LVEF (p<0.001, R20.35), LAVi 




Conclusions – Long-term anthracycline cardiomyopathy is characterized by pathologically 
increased iLVESV. Both LGE and elevated native T1 measurements were associated with 




Anthracycline cardiomyopathy is increasingly recognized as an important contributor to the 
morbidity and mortality of cancer survivors (1). Consequently, international societies have 
published recommendations for the non-invasive monitoring of patients receiving potentially 
cardiotoxic agents (2,3,4). Cardiovascular magnetic resonance (CMR) is the gold standard method 
for measuring ventricular volumes and function and has the unique capability to characterize 
myocardial tissue. CMR studies have focused on the early stages of anthracycline 
cardiomyopathy (5,6,7,8). There are limited longitudinal studies examining cardiovascular 
structure and function over an extended period of time (9,10). 
 
The early stages of anthracycline cardiomyopathy are characterized histologically by myocardial 
edema, inflammation and vacuolisation (11), whereas in the later stages, diffuse myocardial 
fibrosis predominates (12).  Discrete foci of myocardial fibrosis can be detected by late 
gadolinium enhancement (LGE) sequences with broad diagnostic and prognostic applications in 
cardiovascular medicine (13). There are limited, somewhat conflicting data on the presence, 
extent and location of focal myocardial fibrosis detected by LGE in adult patients with 
anthracycline cardiomyopathy, (5,6,10, 14) though it is generally reported to be an infrequent 
finding (11). Furthermore, the qualitative nature of the analysis, which relies on the presence of 
normal myocardium for reference, means that the diffuse fibrosis typically associated with 
anthracycline cardiomyopathy may not be detectible. Novel quantitative techniques such as 
native myocardial T1 mapping and myocardial extracellular volume fraction (ECV) estimation 
using gadolinium-based contrast agents may be better able to detect diffuse fibrosis, with 
accumulating evidence of abnormal values following anthracycline treatment (15,16,17), and 
correlation with exercise capacity (16) and cardiac function (17) reported in paediatric and adult 
populations, respectively.  
 
Therefore, the objectives of this study were to describe the long-term phenotype of anthracycline 
cardiomyopathy, determine the prevalence of focal (LGE) and diffuse (elevated native T1 







Consecutive patients referred for CMR at a tertiary referral center (Bristol Heart Institute, 
Bristol, United Kingdom) between January 2010 and January 2017 were screened for eligibility.  
Inclusion criteria were: age >18 years and evidence of cardiotoxicity after anthracycline 
chemotherapy, which was defined either as an LVEF of <57% or symptoms and/or signs of 
congestive heart failure. Exclusion criteria were: abnormal LV ejection fraction prior to therapy, 
concomitant cardiac disease that could cause heart failure including ischemic heart disease 
(infarct pattern on LGE or inducible myocardial ischemia during pharmacological stress), 
hypertrophic cardiomyopathy, moderate-severe valvular heart disease or valve replacement, 
history of excessive alcohol consumption (>28 standard units per week), active thyroid disease or 
family history of cardiomyopathy in a first degree relative. The local institutional research and 
innovation department (Bristol Royal Infirmary) approved the study and all patients provided 
written consent for use of anonymized data for research purposes at the time of CMR.  
 
Clinical Characteristics 
The following data were collected: demographics, body surface area, body mass index, 
comorbidities, medications, cancer diagnosis, cancer therapy (including date, dose and type of 
therapy), New York Heart Association (NYHA) functional class at the time of CMR, 




CMR - volumes and function 
All patients underwent CMR at 1.5 Tesla (Avanto, Siemens, Erlangen, Germany).  Short-axis 
steady state free precession (SSFP) whole left ventricular (LV) cines (typical scan parameters: 
8mm slice thickness, no slice gap, temporal resolution 38.1ms, echo time 1.07ms, in-plane pixel 
size 1.5 x 0.8mm) were used to determine biventricular volumes, left atrial volumes, left 
ventricular ejection fraction (LVEF) and left ventricular mass, which were indexed to body 
surface area, according to previously described methods (18). All measurements were performed 
by experienced CMR readers (IH/CBD) blinded to clinical details using previously validated (19) 
threshold-detection software (CMR42, Circle Cardiovascular Imaging, Calgary, Canada) by 
manually drawing the epicardial and endocardial borders at end systole and end diastole, taking 
particular care to track the mitral valve plane through the cardiac cycle. 
 
CMR – LGE 
LGE imaging was used to detect focal myocardial fibrosis according to previously described 
methods (18) after the administration of 0.1 mmol/kg Gadovist (Bayer, Reading, United 
Kingdom) with an inversion time progressively set to null normal myocardium. The presence, 
location and extent of LGE in each of the 16 American Heart Association (AHA) segments was 
adjudicated qualitatively by two experienced, independent CMR readers (IH/CBD) with 
consensus required in cases of discrepancy. Patients were divided into groups according to the 




CMR – Native myocardial T1 mapping 
Native myocardial T1 maps were obtained in short axis using the modified look-locker inversion 
recovery sequence i.e. 35° flip angle, 100ms minimum TI, 80ms TI increment, 150ms time delay 
with 5-(3)-3 heartbeat acquisition scheme (20). Regions of interest were drawn on motion-
corrected T1 maps in the mid cavity interventricular septum to determine native myocardial T1 
measurements using Argus software (Siemens, Germany) by an experienced CMR reader (IH), 
avoiding areas exhibiting LGE. Patients were divided into those with normal native myocardial 
T1 measurements (<1065ms) and those with increased native myocardial T1 measurements 
(>1065ms), according to the locally-established normal reference range of 1024  SD  41ms 
(mean  SD  standard deviation) for a control population (21). Secondary analysis, treating native 
myocardial T1 as a continuous variable was undertaken to explore correlations with cardiac 







Descriptive statistics were reported for all study data, including means and standard deviations 
for continuous variables, and counts and percentages for categorical variables. Differences 
between groups were assessed with student t test and Mann-Whitney U test for normally and 
non- normally distributed variables, respectively. Univariate and multivariate linear regression 
models were built to assess the association between outcomes of interest and one or more 
predictors, including controlling for age and gender in some of the associations. A p value < 0.05 
was taken to indicate statistical significance. The analysis was carried out in Stata (Stata v. 13, 




81 patients were eligible for inclusion (62 with LVEF <57% and 19 with symptoms and/or signs 
of heart failure). Their baseline characteristics are summarized in Table 1. Mean age was 55 SD 
14 years; 68% were women. The majority of patients were treated for breast cancer (58%) or 
hematological malignancy (38%).  56 of the patients (69%) had a baseline LVEF >55% on 
echocardiography. Baseline data was not available for 23 patients (28%), commonly because 
their treatment was administered in excess of 10 years prior to CMR. Baseline echo was not 
undertaken in 2 patients (2%) due to perceived low clinical risk of cardiomyopathy. As a 
component of a variety of chemotherapeutic regimens, the mean cumulative equivalent 
doxorubicin dose was 279 SD 89mg/m2 (range 50-450mg/m2). Anthracycline dose did not 
correlate significantly with ventricular volumes or systolic function; neither did the 
administration of radiotherapy (p>0.05 in all cases). Median time from therapy to CMR was 60 
months (interquartile range 17–152 months). Follow-up commenced at the time of referral for 
CMR and medical records were reviewed a median of 21 months (interquartile range 12–33 
months) after CMR. During the study, 28% of the study population were hospitalized with a 
diagnosis of heart failure recorded in their medical records and 6% died. Overall LVEF was 
impaired (49 SD 12%), driven by a pathologically increased  iLVESV (47 SD 23 ml/m2) when 
compared to established normal reference ranges (23). iLVEDV (87 SD 25ml/m2) remained 
within established normal reference ranges, albeit toward the upper limit (23), as did indexed left 
ventricular mass (iLVM) (58 SD 15g/m2).   
 
The predominant left ventricular phenotypes were (Figure 1, Panel A): normal iLVM and normal 
iLVEDV (33%; normal phenotype), normal iLVM and high iLVEDV (22%; eccentric dilatation) 
and small iLVM and normal iLVEDV (21%; myocardial atrophy).  
 
 
LGE imaging for focal myocardial fibrosis 
LGE was observed in 19% of patients and was located exclusively in the mid-myocardium (non-
ischaemic pattern) affecting a mean of 2.6 SD 1.4 segments in each patient. The commonest 
affected myocardial segment was the basal inferoseptal segment (53% of patients with LGE 
exhibited it here; Figure 1. Panel C).  
 
Patients with LGE were more likely to be male (67 vs 36%, p=0.01), have diabetes (13% vs 2%, 
p=0.03) and were scanned at a greater time interval after cancer therapy (153 SD 110 vs 96 SD 
116 months, p=0.02). No other differences in baseline characteristics of patients with and 
without LGE were identified, including cumulative anthracycline dose (310 SD 101 vs 272 SD 
85mg/m2, p=0.23; Table 1.)  
 
Patients with LGE had significantly reduced LVEF (43 SD 11 vs 50 SD 12%, p=0.03) and 
significantly increased  iLVEDV (102 SD 34 vs 83 SD 21 ml/m2, p=0.03), iLVESV (61 SD 32 
vs 43 SD 20ml/m2, p=0.03) and iLVM (65 SD 14 vs 56 SD 14g/m2, p=0.04), compared to those 
without (Table 2.). No significant differences in right ventricular volumes or systolic function, 
MAPSE or LAVi were observed. Hospitalizations with heart failure were similar between 
groups. 2 patients (13%) with LGE died during follow-up in comparison to three (5%) patients 
without (Table 2).  
 
Multivariable regression analysis adjusting for age, sex, and diabetic status showed that the 
presence of LGE had a significant positive association with iLVEDV (p=0.03, CI 2.15-31.0), and 
iLVESV (p=0.03, CI 1.29-28.2) but not with LVEF (p=0.17, CI 11.7-2.08) or other parameters. 
 
Native myocardial T1 mapping techniques  
Native myocardial T1 mapping sequences were available for analysis in a subgroup of 36 
patients. 23 patients (64%) had normal native myocardial T1 measurements (1023 SD 28ms), 
and 13 (36%) had increased native myocardial T1 measurements (1092 SD 20ms) using the 
mean native myocardial T1 + 1 SD (1065ms) of a locally-derived healthy control population as a 
cut point (Table 2.) (21). Baseline characteristics were matched (Table 1).  
 
Patients with increased native myocardial T1 measurements had significantly reduced LVEF (44 
SD 13 vs 55 SD 9%, p=0.01) and significantly increased iLVEDV (97 SD 22 vs 74 SD 19 
ml/m2, p=0.002) and  iLVESV (56 SD 22 vs 35 SD 15ml/m2, p=0.005), compared to those with 
normal measurements, differences which persisted in regression analysis controlling for age and 
sex ( LVEF [p =0.003, CI -20.4–-4.7], iLVEDV [p=0.004, CI 8.8–40.9], iLVESV [p=0.001, CI 
9.9–37.6]. Regression analysis controlling for age and sex also revealed that LAVi was 
significantly increased in patients with increased native myocardial T1 measurements (p=0.02, 
CI 2.3–24.3). Furthermore, hospitalizations for heart failure were higher (38% vs 9%, p=0.03) in 
patients with increased native myocardial T1 measurements. The only death occurred in the 
group with normal native myocardial T1 measurements.  Among patients with increased native 
myocardial T1 measurements, 1 (8%) also had evidence of focal fibrosis by LGE.  
 
Secondary analysis treating native myocardial T1 as a continuous variable demonstrated 
significant positive correlations with iLVEDV (p =<0.001, CI 0.15-0.48, R2 0.33), iLVESV 
(p<0.001, CI 0.15-0.44, R2 0.36), LAVi (p=0.04, CI 0.01 - 0.28, R20.12) and LV mass indexed 
(p=0.01, CI 0.04-0.27, 0.18); and significant negative correlations with LVEF (p<0.001, CI -
0.24- -0.08, R2 0.35) and MAPSE (p =0.02, CI -0.05 - -0.004, R2 0.14) (Figure 2. Panel A-F). In 
31 patients with post-contrast mapping sequences available for analysis, ECV correlated 
significantly with iLVEDV (p=0.003, CI 111-476, R2 0.27) and iLVESV (p=0.02, CI 42-378, R2 
0.18) but not with LVEF (p=0.1, CI -187-18, R2 0.09) or other parameters. 
 
Discussion  
This study provides several insights into the characteristics of late anthracycline cardiomyopathy. 
First, we observed that the primary driver of reduced LVEF in late phase anthracycline 
cardiomyopathy appeared to be a pathological increase in iLVESV and the predominant left 
ventricular phenotypes were: normal mass and normal volume, eccentric dilatation or myocardial 
atrophy with normal volume. Second, the prevalence of focal myocardial fibrosis at median 5 
years post-therapy was relatively low (19%) and distributed exclusively in the mid-myocardium 
with a predilection for the basal and mid interventricular septum. Third, patients with LGE had 
significantly reduced LVEF compared to those without. Fourth, in subgroup analysis, the 
prevalence of elevated native myocardial T1 measurements was relatively high (36%) and these 
patients had significantly reduced systolic function (LVEF), adverse left ventricular remodeling 
and a higher rate of hospitalization for heart failure compared to those with normal native 
myocardial T1 measurements. Fifth, native myocardial T1 measurements and ECV correlated 
with left ventricular volumes, and native T1 also correlated with LVEF but ECV did not. 
 
Cardiac Morphology and Function 
In keeping with previous reports, the predominant mechanism of cardiotoxicity in our cohort was 
a pathological increase in iLVESV (5,7). Both iLVM and iLVEDV, as well as all measures of RV 
volume and systolic function remained within established reference ranges (23). Interestingly, 
iLVEDV was toward the upper limits of normal in the cohort as a whole but pathologically 
elevated in the subgroup of patients with focal fibrosis by LGE, suggesting that patients who 
exhibit focal fibrosis have a more severe or advanced cardiomyopathy than those who do not, 
though this was not associated with adverse clinical outcomes. In addition, a higher iLVM was 
observed in patients with focal fibrosis compared to those without. This elevation in mass is 
likely to be due to eccentric dilatation, rather than true hypertrophy, given that only 1% of the 
population had true LV hypertrophy (defined by a normal iLVEDV and high indexed left 
ventricular mass). Whilst the comparison is not direct, this finding is at odds to a previous report 
correlating lower iLVM with adverse clinical outcomes (9), and may relate to the differing 
timing, methodology and populations of the studies. A recently published longitudinal 
echocardiography study of breast cancer patients described a relative increase in indexed left 
ventricular mass, which was sustained at 3 years of follow-up (24).  Interestingly, cumulative 
anthracycline dose was not significantly associated with ventricular volumes or systolic function, 
which may relate to the relatively small sample size and absence of very high doses of 
anthracycline. 
 
It is interesting to note that there was considerable heterogeneity in the left ventricular 
phenotypes, though the majority of the study population displayed either a normal left ventricular 
phenotype (normal iLVEDV and normal LVMi), eccentric dilatation (normal LVMi and  
elevated iLVEDV), or a phenotype of myocardial atrophy (low LVMi and normal iLVEDV), 
with only a minority (11%) exhibiting the so-called Grinch syndrome phenotype (low iLVEDV 
with or without a normal LVMi) previously described by a paediatric study utilizing 
echocardiography (25). Aside from methodological differences, this may also point to differing 
remodeling between children and adults. 
 
LGE Imaging - focal fibrosis 
 
Commensurate with previous reports of both early (5,10), and late (9) anthracycline 
cardiomyopathy, the prevalence of LGE at a median interval of 5 years post-therapy was low. 
Interestingly, the minority of patients with LGE exhibited significantly higher indexed LV 
volumes and significantly lower LVEF than those without, though no association with adverse 
clinical outcomes was demonstrated. This is in keeping with the published anthracycline 
cardiomyopathy literature to date but inconsistent with meta-analysis of non-ischemic 
cardiomyopathies as a whole, where the presence of LGE predicts adverse cardiovascular 
outcomes (26). The absence of this association could in part be due to the low prevalence of LGE 
and small sample size in studies of anthracycline cardiomyopathy to date but may also represent 
the limitation of this technique to detect the diffuse myocardial fibrosis typically associated with 
anthracycline cardiomyopathy (12).  It is noteworthy that patients with LGE were assessed after a 
significantly greater period than those without, which raises the question as to whether fibrosis 
develops over time and may explain why early studies of anthracycline cardiomyopathy have 
reported such a low prevalence of LGE. However, in univariate regression modeling of LGE, 
time interval between chemotherapy and CMR was not significantly associated with left 




Native myocardial T1 mapping – diffuse fibrosis 
Historically, diffuse myocardial fibrosis has been difficult to detect without the inherent risks 
attached to invasive cardiac biopsy. However, the advent of native myocardial T1 mapping and 
ECV techniques by CMR now permit the quantification of diffuse fibrosis non-invasively (27) 
with excellent reproducibility and robust validation against biopsy-proven collagen volume 
fraction and extracellular space reported in explanted hearts (28) and biopsied patients with 
dilated cardiomyopathy (29). Two previous studies of anthracycline cardiomyopathy in adults 
have described abnormal elevation of ECV in cancer survivors 3 years (15) and 7 years (17) after 
anthracycline treatment. The former established that this elevation occurs independently of other 
risk factors and the latter correlated this elevation directly with left atrial volume and negatively 
with diastolic function, and also described higher ECV in patients with reduced LVEF, compared 
to those with preserved LVEF. A further pediatric study provided complementary data 
correlating native myocardial T1 and ECV with exercise capacity, anthracycline dose and subtle 
ventricular remodeling (16).  Our study complements this work by demonstrating significant 
correlations between absolute native myocardial T1 measurements, ECV and measures of left 
ventricular volumes and systolic function in anthracycline cardiomyopathy and in this regard, 
provides novel insight. Patients with increased native myocardial T1 measurements displayed 
significant adverse left ventricular remodeling and reduced systolic function (as measured by 
LVEF), compared to those with normal native myocardial T1 measurements. A greater number 
of hospitalizations occurred in the sub-group with increased native myocardial T1 measurements. 
In addition, absolute values of native myocardial T1 and ECV correlated significantly with left 
ventricular volumes and native myocardial T1 also correlated with LVEF, MAPSE and LAVi. 
All of which would pathophysiologically suggest a greater burden of diffuse fibrosis in patients 
with larger ventricular volumes and worse systolic function. Finally, it is noteworthy that 13 
(36%) of our subgroup had diffuse fibrosis judged by an abnormal native myocardial T1 
measurement, but only 1 (8%) of these had coexisting evidence of focal fibrosis when assessed 
qualitatively by LGE. Therefore, relying solely on LGE would have misclassified 92% of these 
patients as not having fibrosis. This finding is again in keeping with the histopathological report 
of focal fibrosis in only 10% of explanted hearts with anthracycline cardiomyopathy (12). CMR 
T1 techniques appear to offer additional insight in anthracycline cardiomyopathy, yet the precise 
role of these sequences as a diagnostic tool, method of monitoring and means of guiding therapy 
is yet to be defined and large scale, collaborative effort from multiple stakeholders is warranted. 
 
Study limitations 
This was a retrospective single-center study of a small and relatively heterogeneous cohort of 
patients referred for CMR on clinical grounds and, as such, the findings should be interpreted in 
this context and viewed as hypothesis-generating. The small sample size and low number of 
events mean that firm conclusions, particularly regarding clinical outcomes, cannot be drawn and 
large, prospectively conducted, multicenter studies are warranted to address this area of 
important clinical uncertainty. Native myocardial T1 mapping sequences and ECV estimation 
were not available for the entire study population due to the introduction of this sequence to our 
department in 2015, though we feel that this subgroup provides insight into the utility of this 
sequence in anthracycline cardiomyopathy. Finally, complementary echocardiographic, 
electrocardiographic, blood biomarker (including Troponin and BNP) and histopathological data 
were not consistently available and the cross-sectional design of the study meant that temporal 
changes could not be assessed. A prospective study incorporating these measures prior to, during 
and after cancer therapy could address these limitations.  
Conclusions 
Late stage anthracycline cardiomyopathy is characterized by pathological increase in iLVESV, 
normal or dilated iLVEDV, low (19%) prevalence of focal septal fibrosis identified by LGE, and 
higher (36%) prevalence of diffuse fibrosis identified by elevated native T1 measurements. Both 
forms of fibrosis were associated with adverse left ventricular remodeling and reduced LVEF. A 
higher rate of hospitalization for heart failure was observed in patients with elevated native 





CMR = cardiovascular magnetic resonance 
LGE = late gadolinium enhancement 
LV = left ventricle 
iLVEDV = left ventricular end-diastolic volume indexed 
iLVESV = indexed left ventricular end-systolic volume indexed 
LVEF = left ventricular ejection fraction 
ECV = extracellular volume 
MAPSE = mitral annular plane systolic excursion 
TAPSE = tricuspid annular plane systolic excursion 
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Figure 1. Panel A. Distribution of left ventricular phenotype according to age and sex-adjusted 
left ventricular end-diastolic volume indexed, and age and sex-adjusted left ventricular end-
diastolic mass indexed. Panel B. T1-weighted basal short-axis LGE sequence in a 62 year old 
male with LVEF 33% demonstrating mid-myocardial LGE in the basal inferoseptum (white 
arrow) indicative of focal fibrosis Panel C. Segmental distribution of LGE among subjects with 
mid-myocardial LGE using the American Heart Association (AHA) 16-segment plot. For 
example, in patients with LGE, 8/15 (53%) exhibited basal inferoseptual LGE. LGE = late 
gadolinium enhancement 

Figure 2. Regression analysis of absolute native myocardial T1 measurements, demonstrating significant correlations with: Panel A 
LVEF (%), Panel B iLVEDV, Panel C iLVESV, Panel D LVMi, Panel E MAPSE, and Panel F LAVi. Panel G: Short-axis mid-
ventricular native myocardial T1 colour map demonstrating normal measurements (1010ms) in a 62 year old male with LVEF 60%. 
Panel H: Short-axis mid-ventricular native myocardial T1 colour map demonstrating abnormal measurements (1136ms) in a 55 year 
old female with LVEF 29%.
Table 1: Clinical characteristics of the cohort, according to presence of LGE and native myocardial T1 measurements. 
 
 Cohort 
(n = 81) 
LGE  
(n = 15) 
No LGE 
 (n = 66) 
P Normal T1 
(n=23) 
Elevated T1 
(n = 13) 
P  
Age, yrs 55 SD 14 57 SD 12 54 SD 15 0.55 57 SD 9 49 SD 18 0.25 
Female 55 (68) 6 (33) 49 (64) 0.01 18 (78) 9 (69) 0.55 
Body mass index, kg/m2 27 SD 6 28 SD  5 28 SD 6 0.82 28 SD 6 28 SD  5 0.13 
Body surface area, m2 1.9 SD 0.2 1.97 SD 0.17 1.89 SD 0.23 0.12 1.95  SD  0.23 1.84 SD 0.21 0.12 
Comorbidities 
 Systemic hypertension 
 Diabetes 














































































































 DOX, mg/ m2 
 
279 SD 89 
 
310 SD 101 
 




253.6 SD 89.2 
 
281.8 SD 61.7 
 
0.34 
Radiotherapy 43 (54) 7 (47) 36 (55) 0.50 15 (65) 7 (54) 0.66 
Therapy to CMR, months 60 (17-152) 153  SD 110  96  SD  116 0.02 94  SD 126 93  SD  85 0.53 
Values are mean  SD  SD , n (%), or median (25th to 75th percentile). ACE = angiotensin converting enzyme; ARB = angiotensin II 
receptor blocker; CMR = Cardiovascular magnetic resonance; DOX = Equivalent doxorubicin dose; LGE = late gadolinium enhancement;  
Table 2: CMR, clinical and outcome characteristics according to presence of LGE and native myocardial T1 measurements. 
 Cohort 
(n = 81) 
Patients with 




P Patients with 
normal T1 
(n = 23) 
Patients with 
elevated T1 
(n = 13) 
P 
LV end-diastolic volume index, ml/ m2 
LV end-systolic volume index, ml/m2  
LV stroke volume index, ml/m2 
LV ejection fraction, % 
LV mass index, g/m2 
MAPSE, mm 
Left atrial volume index, ml/m2 
Native myocardial T1 (ms) 
Hematocrit (%) 
Extracellular volume fraction (%) 
87 SD 25 
47 SD 23 
40 SD 9 
49 SD 12.0 
58 SD 15 
12 SD 3 




102 SD 34 
61 SD 32 
41 SD 8 
43 SD 11 
65 SD 14 
11 SD 2 
59 SD 24 
83 SD 21 
43 SD 20 
40 SD 9 
50 SD 12 
56 SD 14 
12 SD 3 








74 SD 19 
35 SD 15 
39 SD 8 
55 SD 9 
50 SD 12 
13 SD 3 
46 SD 14 
1023 SD 20 
37.5 SD 7.1 
28.5 SD 4.1 
97 SD 22 
56 SD 22 
41 SD 9 
44  SD  13 
63 SD  17 
12  SD  3 
56 SD 20 
1092 SD 20 
34.7 SD 7.9 











RV end-diastolic volume index, ml/ m2 
RV end-systolic volume index ml/m2  
RV ejection fraction, % 
TAPSE, mm 
68 SD 16 
31 SD 11 
55 SD 9 
20 SD 5 
69 SD 17 
33 SD 14 
54 SD 9 
21 SD 4 
68 SD  16 
31 SD 10 
55 SD 9 





66 SD 12 
29 SD 8 
57 SD 7 
22 SD 5 
73 SD 15 
35 SD 13 
51  SD  11 






















































Values are mean  and standard deviation (SD), n (%), or median (25th to 75th percentile) 
CMR = Cardiovascular magnetic resonance; LGE = late gadolinium enhancement; LV = left ventricle; MAPSE = mitral annular plane systolic 
excursion; RV = right ventricle; TAPSE = tricuspid annular plane systolic excursion;  
 
 
